中国全科医学
中國全科醫學
중국전과의학
Chinese General Practice
2015年
27期
3324-3327
,共4页
桑泽杰%王华明%纪卫政%任伟新
桑澤傑%王華明%紀衛政%任偉新
상택걸%왕화명%기위정%임위신
肝肿瘤%肝动脉灌注化疗栓塞术%化学疗法,肿瘤,局部灌注%替吉奥%治疗结果
肝腫瘤%肝動脈灌註化療栓塞術%化學療法,腫瘤,跼部灌註%替吉奧%治療結果
간종류%간동맥관주화료전새술%화학요법,종류,국부관주%체길오%치료결과
Liver neoplasms%Transarterial chemoembolization%Chemotherapy,cancer,regional perfusion%Gimeracil and oteracil potassium%Treatment outcome
目的：评价巴塞罗那肝癌（ BCLC）分期B期、C期的原发性肝癌（ HCC）患者在肝动脉灌注化疗栓塞术（ TACE）后长期口服低剂量替吉奥的疗效。方法选取2011年12月—2013年12月在新疆医科大学第一附属医院介入科接受治疗且符合纳入与排除标准的HCC患者53例，按其住院时间顺序分为试验组（28例）和对照组（25例）。试验组TACE后联合口服替吉奥治疗；对照组单纯采用TACE治疗。记录两组患者毒副作用。采用Kaplan-Meier法绘制无疾病进展生存曲线，采用Log-rank检验进行生存曲线的比较。结果试验组无疾病进展时间为8.0～16.3个月，中位无疾病进展时间为12.3个月，95%CI为（11.8，13.3）个月。对照组无疾病进展时间为5.0～11.2个月，中位无疾病进展时间为9.1个月，95%CI为（8.6，9.9）个月。其中3例达部分缓解（PR）者肿瘤缩小后手术切除。试验组患者服用替吉奥后4例腹泻，2例中性粒细胞减少，2例恶心、呕吐，毒副作用在1～2级，发生率分别为14.3%、7.1%和7.1%。试验组无疾病进展时间长于对照组（χ2=35.531，P<0.05）。结论 BCLC分期B期、C期的HCC患者TACE后联合口服替吉奥治疗是一种安全、有效的治疗方法。
目的：評價巴塞囉那肝癌（ BCLC）分期B期、C期的原髮性肝癌（ HCC）患者在肝動脈灌註化療栓塞術（ TACE）後長期口服低劑量替吉奧的療效。方法選取2011年12月—2013年12月在新疆醫科大學第一附屬醫院介入科接受治療且符閤納入與排除標準的HCC患者53例，按其住院時間順序分為試驗組（28例）和對照組（25例）。試驗組TACE後聯閤口服替吉奧治療；對照組單純採用TACE治療。記錄兩組患者毒副作用。採用Kaplan-Meier法繪製無疾病進展生存麯線，採用Log-rank檢驗進行生存麯線的比較。結果試驗組無疾病進展時間為8.0～16.3箇月，中位無疾病進展時間為12.3箇月，95%CI為（11.8，13.3）箇月。對照組無疾病進展時間為5.0～11.2箇月，中位無疾病進展時間為9.1箇月，95%CI為（8.6，9.9）箇月。其中3例達部分緩解（PR）者腫瘤縮小後手術切除。試驗組患者服用替吉奧後4例腹瀉，2例中性粒細胞減少，2例噁心、嘔吐，毒副作用在1～2級，髮生率分彆為14.3%、7.1%和7.1%。試驗組無疾病進展時間長于對照組（χ2=35.531，P<0.05）。結論 BCLC分期B期、C期的HCC患者TACE後聯閤口服替吉奧治療是一種安全、有效的治療方法。
목적：평개파새라나간암（ BCLC）분기B기、C기적원발성간암（ HCC）환자재간동맥관주화료전새술（ TACE）후장기구복저제량체길오적료효。방법선취2011년12월—2013년12월재신강의과대학제일부속의원개입과접수치료차부합납입여배제표준적HCC환자53례，안기주원시간순서분위시험조（28례）화대조조（25례）。시험조TACE후연합구복체길오치료；대조조단순채용TACE치료。기록량조환자독부작용。채용Kaplan-Meier법회제무질병진전생존곡선，채용Log-rank검험진행생존곡선적비교。결과시험조무질병진전시간위8.0～16.3개월，중위무질병진전시간위12.3개월，95%CI위（11.8，13.3）개월。대조조무질병진전시간위5.0～11.2개월，중위무질병진전시간위9.1개월，95%CI위（8.6，9.9）개월。기중3례체부분완해（PR）자종류축소후수술절제。시험조환자복용체길오후4례복사，2례중성립세포감소，2례악심、구토，독부작용재1～2급，발생솔분별위14.3%、7.1%화7.1%。시험조무질병진전시간장우대조조（χ2=35.531，P<0.05）。결론 BCLC분기B기、C기적HCC환자TACE후연합구복체길오치료시일충안전、유효적치료방법。
Objective To evaluate the curative effect after long-term oral administration of low-dose gimeracil and oteracil potassium following transarterial chemoembolization( TACE)on patients with Barcelona clinic liver cancer( BCLC)stage B and C. Methods We enrolled 53 HCC patients who accorded with inclusion and exclusion criteria and were admitted into the First Affiliated Hospital of Xinjiang Medical University From December 2011 to December 2013. According to the sequence of admission,the subjects were divided into two groups:trial group( n=28 )and control group( n =25 ) . The trial group was given TACE and the oral administration of gimeracil and oteracil potassium,and the control group was only administrated with TACE. The toxic and side effects of the two groups were recorded,Kanplan-Meier analysis was conducted to analyze the PFS, and Log-rank test was undertaken to compare the survival curves. Results The PFS time of the trial group was 8. 0 -16. 3 months,the median PFS time was 12. 3 months( 95%CI,11. 8 -13. 3 ) . The PFS time of the control group was 5. 0 -11. 2 months,and the median PFS survival time was 9. 1 months( 95%CI,8. 6 -9. 9 ) . Three patients who had partial response underwent excision surgeries after tumors shrunk. In the trial group,four patients had diarrhea,2 patients had neutropenia,and 2 patients had nausea and vomiting after the administration of gimeracil and oteracil potassium. The toxic and side effect was at grade 1-2,and incidence rates of the three side effects were 14. 3%,7. 1% and 7. 1%. The trial group was longer than control group in PFS time(χ2 =35. 531,P<0. 05). Conclusion TACE combined with oral administration of gimeracil and oteracil potassium is safe and effective in the treatment of patients with BCLC stage B and C.
